Shanghai, China – July 28, 2025 – Neuco United Co., Limited. ("Neuco United") and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma") today announced the signing of an exclusive licensing agreement for the manufacturing and commercialization of AR1001 in Greater China, encompassing in Chinese mainland, Hong Kong Special Administrative Region (SAR), Macau SAR.

AR1001, a highly potent and selective PDE5 inhibitor, is a small molecule oral disease modifying therapy for Alzheimer's disease (AD) treatment. It was developed by AriBio Co., Ltd., a clinical-stage biopharmaceutical company headquartered in South Korea. As of now, the global multi-center Phase III clinical trial of AR1001 in patients with early-stage Alzheimer’s disease is ongoing. Preclinical studies have suggested that AR1001 works through multiple mechanisms including neuroprotection, inhibition of Tau phosphorylation, suppression of inflammatory responses, and improving brain perfusion. Clinical studies by far have demonstrated that AR1001 has favorable safety profiles and blood-brain barrier permeability, and may bring potential therapeutic benefits to patients with early AD (from mild cognitive impairment to mild dementia).

Neuco United and AriBio has an established partnership for co-development of various diagnostics, treatments and AI technology. As the first step of this partnership, Neuco United obtained exclusive rights in AR1001 for the Greater China region from AriBio earlier in 2024 and has since been collaborating with AriBio on the ongoing global Phase 3 clinical trial of AR1001 in patients with early-stage Alzheimer’s disease. The global trial enrolled approximately 1500 patients in North America, Europe, UK, China and South Korea. The new licensing agreement with Fosun Pharma represents a major milestone in the regional strategy to bring AR1001 to patients in China, leveraging Fosun Pharma’s deep commercial and manufacturing capability.

Under the terms of the agreement, Fosun Pharma will gain exclusive rights to manufacture and commercialize AR1001 in the Greater China region. Neuco United will continue its responsibilities in coordinating with AriBio to complete the global Phase 3 program. The transaction includes provisions for upfront and milestone payments, as well as sales commission based on net sales.

Following the signing of the licensing agreement, Neuco United, Fosun Pharma, and AriBio are expected to enter into a technology transfer and supply agreement to support commercial readiness in China. Additionally, Fosun Pharma has expressed strong interest in expanding its AR1001 rights to ASEAN markets. The three parties have agreed to begin prompt negotiations for a broader regional licensing framework covering Southeast Asia.

“This collaboration with Fosun Pharma marks an important step forward in our commitment to deliver AR1001 to Alzheimer’s patients in China,” said Ricky Chen, Chairman and CEO of Neuco United. “Fosun Pharma’s strong commercial presence, regulatory know-how, and manufacturing capabilities make them an ideal partner to ensure that this important therapeutic reaches patient who urgently need new treatment options as soon as possible.”

“Alzheimer's disease, as a neurodegenerative disease, still represents a significant unmet clinical need globally.” said Chen Yuqing, Chairman of Fosun Pharma, “Fosun Pharma has always been committed to exploring and promoting innovative drugs and therapies capable of truly changing the treatment course of such diseases. The collaboration with Neuco United marks a crucial step forward in achieving this goal, and we look forward to working closely together to fully leverage Fosun Pharma’s expertise in clinical research and development, commercialization, and manufacturing. This will accelerate the launch of AR1001 in China and bring new hope and treatment options to Chinese patients with Alzheimer's disease."

-END-

About Fosun Pharma

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; SSE: 600196, HKEX: 02196) is a leading innovation-driven global healthcare company operating in the fields of pharmaceuticals, medical devices & diagnostics, and healthcare services. Through its strategic alliance with Sinopharm Group Co., Ltd., Fosun Pharma further extends its capabilities in pharmaceutical commerce. Over the past 30 years since its establishment, Fosun Pharma has maintained deep roots in China while strategically expanding its global presence. The company has been actively implementing its “4IN” strategy - Innovation, Internationalization, Intelligentization, and Integration, with core business operations now spanning major overseas markets including the United States, Europe, Africa, India, and Southeast Asia. At present, Fosun Pharma has established an open and globally integrated pharmaceutical R&D ecosystem, focusing on core therapeutic areas including oncology (solid tumors and hematologic malignancies) and Immune-inflammatory disorders. The company is strategically enhancing its technological leadership in antibody/ADC platforms, cell therapies, and small molecule development, while collaborating with industry funds to pioneer next-generation modalities such as radiopharmaceuticals, RNA therapeutics, gene editing, and AI-powered drug discovery. This multidimensional approach accelerates the translation of innovative therapies into clinical practice, systematically addressing critical unmet medical needs worldwide.

About Neuco United

Neuco United is an biotechnology company headquartered in Hong Kong. It was founded by a team of seasoned professionals with years of successful experience in original innovative drug discovery, clinical development, as well as regulatory affairs in the global biopharmaceutical industry. The company focuses on the research and development of innovative drugs for neurodegenerative diseases, particularly Alzheimer’s disease (AD), as well as on AI-driven drug discovery platforms and blood-based diagnostic testing for AD. In addition, Neuco United has obtained the exclusive license from AriBio Co., Ltd. for the development and commercialization ofAR1001 in Greater China.

About AriBio Co., Ltd.

Founded in 2010, AriBio is a clinical-stage biopharmaceutical company headquartered in South Korea, with offices located in the United States to manage global clinical operations and regulatory affairs. The company focuses on the development of novel therapies for neurodegenerative diseases, including Alzheimer’s disease. AriBio continues to expand its partnerships to accelerate the development and delivery of life-changing treatments to patients worldwide. AriBio plans to expand its partnership with Neuco for the Asian territories for the development of future pipeline for neurodegenerative diseases.